Luciferase assay using hepatocellular carcinoma cells showed that OA competitively suppressed the activity of FXR-LBD induced by its endogenous activator chenodoxycholic acid (CDCA) without affecting the latter’s metabolism. This evidence concerns the gene NR1H4 and hepatocellular carcinoma.